192 related articles for article (PubMed ID: 33561465)
1. The role of androgen therapy in prostate cancer: from testosterone replacement therapy to bipolar androgen therapy.
Xie T; Song XL; Wang C; Yu YZ; Wang JQ; Chen ZS; Zhao SC
Drug Discov Today; 2021 May; 26(5):1293-1301. PubMed ID: 33561465
[TBL] [Abstract][Full Text] [Related]
2. Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study.
Teply BA; Wang H; Luber B; Sullivan R; Rifkind I; Bruns A; Spitz A; DeCarli M; Sinibaldi V; Pratz CF; Lu C; Silberstein JL; Luo J; Schweizer MT; Drake CG; Carducci MA; Paller CJ; Antonarakis ES; Eisenberger MA; Denmeade SR
Lancet Oncol; 2018 Jan; 19(1):76-86. PubMed ID: 29248236
[TBL] [Abstract][Full Text] [Related]
3. Is testosterone treatment good for the prostate? Study of safety during long-term treatment.
Feneley MR; Carruthers M
J Sex Med; 2012 Aug; 9(8):2138-49. PubMed ID: 22672563
[TBL] [Abstract][Full Text] [Related]
4. Monitoring androgen replacement therapy: testosterone and prostate safety.
Morales A
J Endocrinol Invest; 2005; 28(3 Suppl):122-7. PubMed ID: 16042371
[TBL] [Abstract][Full Text] [Related]
5. [Bipolar androgen therapy: A novel therapeutic strategy for castration-resistant prostate cancer].
Hu YH; Guo JC; Zhang M
Zhonghua Nan Ke Xue; 2017 Dec; 23(12):1138-1140. PubMed ID: 29738189
[TBL] [Abstract][Full Text] [Related]
6. Association of Testosterone Replacement With Cardiovascular Outcomes Among Men With Androgen Deficiency.
Cheetham TC; An J; Jacobsen SJ; Niu F; Sidney S; Quesenberry CP; VanDenEeden SK
JAMA Intern Med; 2017 Apr; 177(4):491-499. PubMed ID: 28241244
[TBL] [Abstract][Full Text] [Related]
7. The effect of androgen supplementation therapy on the prostate.
Kaufman JM
Aging Male; 2003 Sep; 6(3):166-74. PubMed ID: 14628497
[TBL] [Abstract][Full Text] [Related]
8. Testosterone therapy and prostate cancer--safety concerns are well founded.
Klotz L
Nat Rev Urol; 2015 Jan; 12(1):48-54. PubMed ID: 25563848
[TBL] [Abstract][Full Text] [Related]
9. The testosterone paradox of advanced prostate cancer: mechanistic insights and clinical implications.
Kumar R; Sena LA; Denmeade SR; Kachhap S
Nat Rev Urol; 2023 May; 20(5):265-278. PubMed ID: 36543976
[TBL] [Abstract][Full Text] [Related]
10. Safety of androgen therapy in men with prostate cancer.
Rajan P; Tharakan T; Chen R
Best Pract Res Clin Endocrinol Metab; 2022 Sep; 36(5):101628. PubMed ID: 35248487
[TBL] [Abstract][Full Text] [Related]
11. Prostate cancer risk in testosterone-treated men.
Raynaud JP
J Steroid Biochem Mol Biol; 2006 Dec; 102(1-5):261-6. PubMed ID: 17113983
[TBL] [Abstract][Full Text] [Related]
12. Safety of testosterone therapy in men with prostate cancer.
Morgentaler A; Caliber M
Expert Opin Drug Saf; 2019 Nov; 18(11):1065-1076. PubMed ID: 31495240
[No Abstract] [Full Text] [Related]
13. Questioning the evidence behind the Saturation Model for testosterone replacement therapy in prostate cancer.
Kim JW
Investig Clin Urol; 2020 May; 61(3):242-249. PubMed ID: 32377599
[TBL] [Abstract][Full Text] [Related]
14. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
Coward RM; Simhan J; Carson CC
BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
[TBL] [Abstract][Full Text] [Related]
15. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
16. Testosterone replacement therapy (TRT) and prostate cancer: An updated systematic review with a focus on previous or active localized prostate cancer.
Lenfant L; Leon P; Cancel-Tassin G; Audouin M; Staerman F; Rouprêt M; Cussenot O
Urol Oncol; 2020 Aug; 38(8):661-670. PubMed ID: 32409202
[TBL] [Abstract][Full Text] [Related]
17. [Testosterone replacement therapy and prostate cancer: the downfall of a paradigm?].
Castillo OA; López-Fontana G; Vidal-Mora I; López Laur JD
Medwave; 2015 Apr; 15(3):e6115. PubMed ID: 25919660
[TBL] [Abstract][Full Text] [Related]
18. Bipolar Androgen Therapy for Men With Androgen Ablation Naïve Prostate Cancer: Results From the Phase II BATMAN Study.
Schweizer MT; Wang H; Luber B; Nadal R; Spitz A; Rosen DM; Cao H; Antonarakis ES; Eisenberger MA; Carducci MA; Paller C; Denmeade SR
Prostate; 2016 Sep; 76(13):1218-26. PubMed ID: 27338150
[TBL] [Abstract][Full Text] [Related]
19. Bipolar androgen therapy (BAT): A patient's guide.
Denmeade S; Antonarakis ES; Markowski MC
Prostate; 2022 May; 82(7):753-762. PubMed ID: 35357024
[TBL] [Abstract][Full Text] [Related]
20. Reversing the effects of androgen-deprivation therapy in men with metastatic castration-resistant prostate cancer.
Marshall CH; Tunacao J; Danda V; Tsai HL; Barber J; Gawande R; Weiss CR; Denmeade SR; Joshu C
BJU Int; 2021 Sep; 128(3):366-373. PubMed ID: 33765326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]